BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

689 related articles for article (PubMed ID: 32424595)

  • 21. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
    Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
    World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
    Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The platelet-to-lymphocyte ratio predicts poor survival in patients with huge hepatocellular carcinoma that received transarterial chemoembolization.
    Xue TC; Jia QA; Ge NL; Zhang BH; Wang YH; Ren ZG; Ye SL
    Tumour Biol; 2015 Aug; 36(8):6045-51. PubMed ID: 25731733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutrophil-to-lymphocyte and aspartate-to-alanine aminotransferase ratios predict hepatocellular carcinoma prognosis after transarterial embolization.
    Liu C; Jia BS; Zou BW; Du H; Yan LN; Yang JY; Jiang L; Wen TF; Lu WS
    Medicine (Baltimore); 2017 Nov; 96(45):e8512. PubMed ID: 29137051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization.
    Gu J; Zhang X; Cui R; Zhang J; Wang Z; Jia Y; Miao R; Dong Y; Ma X; Fan H; Wang H; Ren L; Li Y; Niu W; Zhang J; Qu K; Liu C
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):836-844. PubMed ID: 30614882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular Carcinoma.
    Reis SP; Sutphin PD; Singal AG; Grzybowski R; Fisher S; Ball C; Xi Y; Grewal S; Kalva SP
    J Comput Assist Tomogr; 2017; 41(2):289-293. PubMed ID: 27824665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of neutrophil to lymphocyte ratio in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Xu X; Chen W; Zhang L; Miao R; Zhou Y; Wan Y; Dong Y; Liu C
    Chin Med J (Engl); 2014; 127(24):4204-9. PubMed ID: 25533822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of inflammatory and nutritional markers for hepatocellular carcinoma.
    Xu Y; Yuan X; Zhang X; Hu W; Wang Z; Yao L; Zong L
    Medicine (Baltimore); 2021 Jun; 100(25):e26506. PubMed ID: 34160470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
    Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
    Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
    Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio.
    Sun W; Zhang L; Luo M; Hu G; Mei Q; Liu D; Long G; Hu G
    Head Neck; 2016 Apr; 38 Suppl 1():E1332-40. PubMed ID: 26362911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
    Wen P; Chen SD; Wang JR; Zeng YH
    Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
    Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
    World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
    Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS; Li HZ; Ma C; Xiao YD
    BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of inflammation-based indices in patients with resected hepatocellular carcinoma.
    Kong W; Yang M; Zhang J; Cheng Y; Dai T; Zhang J; Wang G; Zhang J
    BMC Cancer; 2021 Apr; 21(1):469. PubMed ID: 33906632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monocyte/granulocyte to lymphocyte ratio and the MELD score as predictors for early recurrence of hepatocellular carcinoma after trans-arterial chemoembolization.
    Elalfy H; Besheer T; El-Maksoud MA; Farid K; Elegezy M; El Nakib AM; El-Aziz MA; El-Khalek AA; El-Morsy A; Elmokadem A; Elsamanoudy AZ; El-Bendary M
    Br J Biomed Sci; 2018 Oct; 75(4):187-191. PubMed ID: 29991324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma.
    Huszno J; Kolosza Z; Mrochem-Kwarciak J; Rutkowski T; Skladowski K
    Oncology; 2019; 97(1):7-17. PubMed ID: 31048577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.